天臣医疗(688013) - 2023 Q4 - 年度业绩(更正)

Financial Performance - Total operating revenue for 2023 was revised to RMB 253,645,801.13, a decrease of 1,180.02 million from the previous report, reflecting a year-on-year increase of 9.31%[3] - The net profit attributable to the parent company was adjusted to RMB 47,311,219.20, down by 534.93 million, representing a decrease of 10.16% compared to the previous report[4] - Basic earnings per share were revised to RMB 0.58, a decrease of 0.07 from the previous report, reflecting a decline of 10.77%[4] - The net profit after deducting non-recurring gains and losses was adjusted to RMB 37,554,404.83, a decrease of 539.95 million, representing a decline of 12.57%[4] Assets and Equity - Total assets at the end of the reporting period were RMB 626,608,586.15, an increase of 15.30% from the beginning of the period[3] - The total equity attributable to the parent company was revised to RMB 571,524,539.79, an increase of 12.41% from the previous year[3] - The weighted average return on net assets increased to 9.70%, up by 0.38 percentage points compared to the previous year[3] Adjustments and Communication - The company expressed apologies for any inconvenience caused to investors due to the adjustments made after thorough communication with auditors[4] - The adjustments were made due to changes in market conditions and further understanding of customer and business information[4] - The company emphasized that the financial data provided are preliminary and subject to final audit in the annual report[5]